Although a recent study illustrated a mouse model of AATD with CRISPR editing of all five murine AAT genes [11], the antisense oligonucleotide (ASO) approach provides insights about short-term effects and dose dependent responses by targeting the common coding sequences. The gene discussed is SERPINA1; the disease is alpha 1-antitrypsin deficiency.